Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (CREDO 3)

A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy

The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with an existing medication called a tumour necrosis factor alpha inhibitor

The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by TNF-α inhibitor (TNFi) therapy.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Drug: Olokizumab; Drug: Placebo

Detailed Description

The goal of this Phase III study was to assess the efficacy, safety and tolerability of OKZ in subjects with moderately to severely active RA who had responded inadequately to TNFi therapy. The primary endpoint of the trial was assessed at Week 12. Olokizumab was expected to reduce the disease activity and improve physical function. The study was expected to provide safety information in a large group of subjects over at least a 24 week period.

This was a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. This study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to Week 24, and a Safety FollowUp Period from Week 24 to Week 44.

A total of 350 subjects were planned to be randomized.Subjects were assessed for eligibility to enter the study during a 4-week Screening Period. Eligible subjects were randomized at Visit 2 in a 2:2:1 ratio in one of 3 treatment groups (planned 140, 140, and 70 subjects per group, respectively) :

1. Olokizumab 64 mg q4w: SC injection of OKZ 64 mg q4w (alternating with SC injection of placebo OKZ q4w to maintain blinding) + MTX for 24 weeks,
2. Olokizumab 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX for 24 weeks or
3. Placebo: SC injection of placebo q2w + MTX for 16 weeks.

Subjects who received placebo were re-randomized at Week 16 to receive 64 mg OKZ q4w + Methotrexate or 64 mg OKZ q2w +Methotrexate for 8 weeks.

Throughout the double-blind Treatment Period, all subjects were required to remain on a stable dose of background MTX with a stable route of administration. Concomitant treatment with folic acid was required for all subjects. The last dose of OKZ was administered at Week 20 for subjects receiving OKZ 64 mg q4w and at Week 22 for subjects receiving OKZ 64 mg q2w.

Following Visit 2 (randomization; Week 0), subjects returned to the study site at least every 2 weeks through Week 24 for response and safety assessments.

At Week 14, subjects who did not improve by at least 20% in both swollen and tender joint counts were classified as nonresponders and were administered sulfasalazine and/or hydroxychloroquine as rescue medication in addition to the assigned treatment.

After completion of the 24-week double-blind Treatment Period, subjects either rolled over into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after the last dose of study treatment.

Subjects who discontinued randomized treatment prematurely were required to come for the End of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then continue with the scheduled study visits.

Adverse events (AEs) were assessed throughout the study (starting when the subject signed the informed consent form) and evaluated using the Common Terminology Criteria for Adverse Events Version 4.0. There was ongoing monitoring of safety events, including laboratory findings, by the Sponsor or the Sponsor's designee. In addition, safety was assessed throughout the study by an independent Data Safety Monitoring Board and potential major adverse cardiac events were evaluated by an independent Cardiovascular Adjudication Committee.

The study was conducted at 123 sites across 11 countries globally (in US,EU, Russian Federation, Asia, Latin America)

• Study Type: Interventional
• Enrollment (Actual): 368
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Ciudad Autonoma Buenos Aires, Argentina, C1015ABO
    • Organización Médica de Investigación (OMI)
  • Ciudad Autonoma Buenos Aires, Argentina, C1204AAD
    • Instituto Centenario
  • Ciudad Autonoma Buenos Aires, Argentina, 1426
    • Atencion Integral en Reumatologia (AIR)
  • Ciudad Autonoma Buenos aires, Argentina, C1046AAQ
    • APRILLUS
  • Cordoba, Argentina, 5016
    • Hospital Privado Centro Medico de Cordoba S.A
  • San Juan, Argentina, 5400
    • Centro Polivalente de Asistencia e Inv. Clinica CER
  • Buenos Aires
    • Mar del Plata, Buenos Aires, Argentina, B7600FYK
      • Centro de Investigaciones Medicas Mar Del Plata
    • Mar del Plata, Buenos Aires, Argentina, B7600FZN
      • Instituto de Investigaciones Clinicas
    • Quilmes, Buenos Aires, Argentina, B1878GEG
      • Instituto de Investigaciones Clinicas Quilmes
  • Santa Fe
    • Rosario, Santa Fe, Argentina, S2000CFJ
      • Clinica de Higado y Aparato Digestivo
    • Venado Tuerto, Santa Fe, Argentina, S2600KUE
      • Sanatorio San Martin
  • Tucuman
    • San Miguel de Tucuman, Tucuman, Argentina, T4000AXL
      • Centro Medico Privado de Reumatologia
    • San Miguel de Tucuman, Tucuman, Argentina, T4000BRD
      • Centro de Investigaciones Reumatológicas
• Brazil
  • Santa Catarina, Brazil, 88301-215
    • Clínica de Neoplasias Litoral Ltda.
  • Sao Paulo, Brazil, 04032-060
    • Associação de Assistência à Criança Deficiente - AACD
  • São Paulo, Brazil, 01228-200
    • CPCLIN - Centro de Pesquisas Clínicas Ltda.
  • Ceará
    • Fortaleza, Ceará, Brazil, 60430-370
      • HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará
  • Espírito Santo
    • Vitória, Espírito Santo, Brazil, 29055450
      • CEDOES - Diagnóstico e Pesquisa
  • Goiás
    • Goiânia, Goiás, Brazil, 74110-120
      • CIP - Centro Internacional de Pesquisa
  • Minas Gerais
    • Juiz de Fora, Minas Gerais, Brazil, 36010-570
      • CMiP - Centro Mineiro de Pesquisa
  • Paraná
    • Curitiba, Paraná, Brazil, 80030-110
      • CETI - Centro de Estudos em Terapias Inovadoras Ltda.
  • Rio Grande Do Sul
    • Lajeado, Rio Grande Do Sul, Brazil, 95900-010
      • Hospital Bruno Born
    • Porto Alegre, Rio Grande Do Sul, Brazil, 90480-000
      • LMK Serviços Médicos S/S Ltda
  • Sao Paulo
    • Santo André, Sao Paulo, Brazil, 09060-650
      • Faculdade de Medicina do ABC
    • Sao Bernardo Do Campo, Sao Paulo, Brazil, 09715-090
      • Centro Multidisciplinar de Estudos Clínicos - CEMEC
• Colombia
  • Barranquilla, Colombia, 80020
    • Centro de Reumatologia y Ortopedia SAS
  • Bogotá, Colombia, 110221
    • Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM
  • Bucaramanga, Colombia, 680003
    • Medicity S.A.S.
  • Cali, Colombia, 76001
    • Clinica de Artritis Temprana S.A.
• Czechia
  • Ostrava - Moravska Ostrava, Czechia, 70200
    • Revmatologie MUDr. Klara Sirova s.r.o.
  • Pardubice, Czechia, 53002
    • CCR Czech, a.s.
  • Uherske Hradiste, Czechia, 68601
    • MEDICAL Plus s.r.o.
  • Zlin, Czechia, 760 01
    • PV - MEDICAL, s.r.o.
• Germany
  • Hamburg, Germany, 20095
    • HRF Hamburger Rheuma Forschungszentrum
  • Hessen
    • Bad Nauheim, Hessen, Germany, 61231
      • Kerckhoff-Klinik gGmbH
  • Sachsen Anhalt
    • Magdeburg, Sachsen Anhalt, Germany, 39120
      • SMO.MD GmbH
• Hungary
  • Budapest, Hungary, 1036
    • Óbudai Egészségügyi Centrum
  • Budapest, Hungary, 1033
    • Clinexpert Egeszsegugyi Szolg. es Ker. Kft.
  • Szolnok, Hungary, 5000
    • MAV Korhaz es Rendelointezet
  • Veszprem, Hungary, 8200
    • Vital Medical Center
• Korea, Republic of
  • Gwangju, Korea, Republic of, 61469
    • Chonnam National University Hospital
  • Gyeonggi-do, Korea, Republic of, 431-796
    • Hallym University Sacred Heart Hospital
  • Seoul, Korea, Republic of, 3722
    • Severance Hospital, Yonsei University
  • Gyeonggi-do
    • Suwon-si, Gyeonggi-do, Korea, Republic of, 443-380
      • Ajou University Hospital
• Mexico
  • Chihuahua, Mexico, 31000
    • Investigacion y Biomedicina de Chihuahua, S.C.
  • Distrito Federal
    • Mexico, Distrito Federal, Mexico, 06700
      • Clinstile, S.A. de C.V.
    • Mexico, Distrito Federal, Mexico, 03720
      • Centro de Investigacion Clínica GRAMEL S.C
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44650
      • Clinica de Investigacion en Reumatologia y Obesidad S.C.
    • Guadalajara, Jalisco, Mexico, 44690
      • Centro de Estudios de Investigacion Basica Y Clinica SC
  • Nuevo León
    • Monterrey, Nuevo León, Mexico, 64000
      • Accelerium S. de R.L. de C.V.
    • Monterrey, Nuevo León, Mexico, 64460
      • Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez
  • San Luis Potos
    • San Luis Potosi, San Luis Potos, Mexico, 78213
      • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.
• Poland
  • Bydgoszcz, Poland, 85-168
    • Szpital Uniwersytecki nr 2 im.dr J. Biziela
  • Grodzisk Mazowiecki, Poland, 05-825
    • McBk S.C.
  • Lodz, Poland, 91-363
    • Centrum Medyczne AMED
  • Sieradz, Poland, 98-200
    • Szpital Wojewodzki im. Prymasa Kardynala Stefana Wyszynskiego
  • Tomaszow Lubelski, Poland, 22-600
    • Samodzielny Publiczny ZOZ Tomaszow Lubelski
  • Warszawa, Poland, 02-777
    • McM Polimedica
• Russian Federation
  • Moscow, Russian Federation, 115522
    • FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"
  • Moscow Region
    • Moscow, Moscow Region, Russian Federation, 111539
      • State Budgetary Healthcare Institution "City Clinical Hospital # 15 n.a O.M. Filatov" of Moscow Healtheare Department
  • Novosibirsk Oblast
    • Novosibirsk, Novosibirsk Oblast, Russian Federation, 630099
      • City Clinical Hospital #1
  • Omsk Oblast
    • Omsk, Omsk Oblast, Russian Federation, 644024
      • Diagnostic Center Ultramed
  • Republic Of Karelia
    • Petrozavodsk, Republic Of Karelia, Russian Federation, 185019
      • SBHI of the Republic of Karelia "Republican Hospital named after V.A.Baranov"
  • Rostov Oblast
    • Rostov-on-Don, Rostov Oblast, Russian Federation, 344022
      • Rostov State Medical Unversity
  • Stavropol Region
    • Stavropol', Stavropol Region, Russian Federation, 355030
      • SBHI of Stavropol Region "Stavropol Regional Clinical Hospital"
  • Vladimir Oblast
    • Vladimir, Vladimir Oblast, Russian Federation, 600023
      • Regional Clinical Hospital
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85032
      • Arizona Arthritis & Rheumatology Associates, P.C.
  • Arkansas
    • Hot Springs, Arkansas, United States, 71913
      • CHI St. Vincent Hot Springs
  • California
    • Covina, California, United States, 91722
      • Medvin Clinical Research
    • El Cajon, California, United States, 92020-4124
      • TriWest Research Associates, LLC
    • Fullerton, California, United States, 92835
      • Saint Jude Heritage Medical Grp
    • Hemet, California, United States, 92543
      • С V Mehta MD Med Corp.
    • Lakewood, California, United States, 90623
      • Advanced Medical Research, LLC
    • Palo Alto, California, United States, 94304
      • Stanford University School of Medicine
    • Riverside, California, United States, 92506
      • Riverside Medical Clinic
    • San Leandro, California, United States, 94578
      • East Bay Rheumatology Medical Group, Inc.
    • Upland, California, United States, 91786
      • Inland Rheumatology Clinical Trials, Inc.
  • Colorado
    • Denver, Colorado, United States, 80230
      • Denver Arthritis Clinic
  • Delaware
    • Newark, Delaware, United States, 19713
      • Javed Rheumatology Associates
  • Florida
    • Boca Raton, Florida, United States, 33486
      • RASF - Clinical Research Center
    • Miami, Florida, United States, 33135
      • Suncoast Research Group LLC
    • Orlando, Florida, United States, 32810
      • Omega Research Consultants
    • Pembroke Pines, Florida, United States, 33026
      • Family Clinical Trials, LLC.
    • Tampa, Florida, United States, 33614
      • AdventHealth Medical Group, PA
  • Idaho
    • Idaho Falls, Idaho, United States, 83404
      • Institute of Arthritis Research
  • Kansas
    • Kansas City, Kansas, United States, 66160
      • University of Kansas Hospital
  • Kentucky
    • Bowling Green, Kentucky, United States, 42101
      • Graves Gilbert Clinic
  • Louisiana
    • Monroe, Louisiana, United States, 71203
      • The Arthritis & Diabetes Clinic, Inc.
  • Maryland
    • Hagerstown, Maryland, United States, 21740
      • Klein and Associates, M.D., P.A.
    • Wheaton, Maryland, United States, 20902
      • The Center for Rheumatology and Bone Research
  • Massachusetts
    • Worcester, Massachusetts, United States, 01605
      • Clinical Pharmacology Study Group
  • Montana
    • Kalispell, Montana, United States, 59901
      • Glacier View Research Instutute-Rheumatology
  • New Jersey
    • Freehold, New Jersey, United States, 07728
      • Arthritis & Osteoporosis Associates, PA
  • New Mexico
    • Albuquerque, New Mexico, United States, 87114
      • Lovelace Scientific Resources, Inc.
  • New York
    • New York, New York, United States, 11201
      • NYU Langone Ambulatory Care
  • North Carolina
    • Greensboro, North Carolina, United States, 27408
      • Medication Management, LLC
    • Leland, North Carolina, United States, 28451
      • Cape Fear Arthritis Care
    • Wilmington, North Carolina, United States, 28401
      • Carolina Arthritis Associates
  • North Dakota
    • Minot, North Dakota, United States, 58701
      • Trinity Medical Group
  • Ohio
    • Cincinnati, Ohio, United States, 45242
      • Cincinnati Rheumatic Disease Study Group
    • Dayton, Ohio, United States, 45417
      • STAT Research, Inc.
    • Perrysburg, Ohio, United States, 43606
      • Clinical Research Source, Inc.
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19152
      • Arthritis Group
  • South Carolina
    • Charleston, South Carolina, United States, 29486
      • Low Country Research Center
  • Texas
    • Amarillo, Texas, United States, 79124
      • Amarillo Center for Clinical Research
    • Austin, Texas, United States, 78731
      • Austin Regional Clinic, P.A.
    • Baytown, Texas, United States, 77521
      • Accurate Clinical Research, Inc.
    • Grapevine, Texas, United States, 76034
      • Precision Comprehensive Clinical Research Solutions
    • Houston, Texas, United States, 77065
      • Rheumatology Clinic of Houston, P.A.
    • Houston, Texas, United States, 77089
      • Accurate Clinical Research, Inc.
    • Houston, Texas, United States, 77429
      • Pioneer Research Solutions, Inc.
    • Houston, Texas, United States, 77004
      • Therapeutic Concepts Rheumatology, LLC
    • League City, Texas, United States, 77573
      • Accurate Clinical Research, Inc.
    • Lubbock, Texas, United States, 79410
      • Endocrinology, Internal Medicine
    • San Antonio, Texas, United States, 78229
      • Dr. Alex De Jesus Rheumatology, P.A.
    • Woodville, Texas, United States, 77382
      • Advanced Rheumatology of Houston

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Subjects may be enrolled in the study only if they meet all of the following criteria.

• Subjects willing and able to sign informed consent
• Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised classification criteria for RA for at least 24 weeks prior to Screening.

(If the subject was diagnosed according to ACR 1987 criteria previously, the Investigator may classify the subject per ACR 2010 retrospectively, using available source data.)

• Treatment with oral, SC, or intramuscular (IM) MTX for at least 12 weeks prior to Screening at a dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented intolerance to higher doses)

  • The dose and means of administering MTX must have been stable for at least 6 weeks prior to Screening.
• Subjects must be willing to take folic acid or equivalent throughout the study.

• Subjects must have moderately to severely active RA disease as defined by all of the following:

  • ≥6 tender joints (68 joint count) at Screening and baseline; and
  • ≥6 swollen joints (66 joint count) at Screening and baseline; and
  • C-reactive protein (CRP) above Upper limit of normal (ULN) at Screening based on the central laboratory results.

• Subjects must have a documented inadequate response to treatment (i.e., TNFi failure) with ≥1 licensed TNFi following at least 12 weeks of therapy with that agent. Inadequate response to treatment is classified as either:

  • Primary failure: The absence of any documented clinically significant response; or
  • Secondary failure: Documented initial response with subsequent loss of that response or partial response

Exclusion Criteria:

• Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g., gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus) (However, subjects may have secondary Sjogren's syndrome or hypothyroidism.)
• Subjects who are Steinbrocker class IV functional capacity (incapacitated, largely or wholly bed-ridden or confined to a wheelchair, with little or no self-care)
• Prior exposure to any licensed or investigational compound directly or indirectly targeting Interleukin (IL) 6 or IL 6R (including tofacitinib or other Janus kinases and spleen tyrosine kinase [SYK] inhibitors)
• Prior treatment with cell depleting therapies including anti CD20 or investigational agents (e.g., CAMPATH, anti CD4, anti CD5, anti CD3, and anti CD19) with the exception of rituximab, which is allowed if it was discontinued at least 24 weeks prior to baseline (rituximab should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA).

• Prior use of bDMARDs, within the following windows prior to baseline (bDMARDs should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):

  1. 4 weeks for etanercept and anakinra
  2. 8 weeks for infliximab
  3. 10 weeks for adalimumab, certolizumab, and golimumab
  4. 12 weeks for abatacept
• Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to baseline
• Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or change in dosage within 2 weeks prior to baseline
• Prior documented history of no response to hydroxychloroquine and sulfasalazine

• Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):

  1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine, chloroquine, gold, penicillamine, minocycline, or doxycycline
  2. 12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a dosage of 50 grams 4 times daily for at least 24 hours
  3. 24 weeks for cyclophosphamide
• Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination with live vaccines during the study
• Participation in any other investigational drug study within 30 days or 5 times the terminal half-life of the investigational drug, whichever is longer, prior to baseline
• Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to baseline
• Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline
• Use of non steroidal anti inflammatory drugs (NSAIDs) on unstable dose or switching of NSAIDs within 2 weeks prior to baseline
• Previous participation in this study (randomized) or another study of OKZ

• Subjects with concurrent acute or chronic viral Hepatitis B or C infection as detected by blood tests at Screening (e.g., positive for hepatitis B surface antigen [HBsAg], total hepatitis B core antibody [anti-HBc], or hepatitis C virus antibody [HCV Ab])

  a) subjects who are positive for hepatitis B surface antibodies (anti-HBs), but negative for HBsAg and anti-HBc, will be eligible.

• Subjects with HIV infection

• Subjects with:

  1. Suspected or confirmed current active tuberculosis (TB) disease or a history of active TB disease.
  2. Close contact (i.e., sharing the same household or other enclosed environment, such as a social gathering place, workplace, or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening
• Concurrent malignancy or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma of the cervix in situ and successfully treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to Screening [and no more than 3 excised skin cancers within the last 5 years prior to Screening])
• Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2 weeks prior to Screening or at baseline, injectable anti-infective therapy in the last 4 weeks prior to baseline, or serious or recurrent infection with history of hospitalization in the 6 months prior to baseline
• Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other non-self-limited herpes zoster infections in the 6 months prior to baseline
• Subjects with planned surgery during the study or surgery ≤ 4 weeks prior to Screening and from which the subject has not fully recovered, as judged by the Investigator
• Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with history of such predisposing conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)
• Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis and optic neuritis)
• History of chronic alcohol or drug abuse as judged by the Investigator
• Subjects with a known hypersensitivity to any component of the OKZ drug product or placebo
• Subjects with a known hypersensitivity or contraindication to any component of the rescue medication
• History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
• Female subjects who are pregnant, currently lactating, have lactated within the last 12 weeks, or who are planning to become pregnant during the study or within 6 months of the last dose of study treatment
• Female subjects of childbearing potential (unless permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels >40 mIU/mL and estradiol <20 pg/mL) who are not willing to use a highly effective method of contraception during the study and for at least 6 months after the last administration of study treatment

OR

Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 2: Olokizumab q2w; Olokizumab 64mg subcutaneous q2w + Methotrexate 64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)	Drug: Olokizumab; 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
Placebo Comparator: Arm 3: Placebo q2w; Placebo q2w subcutaneous + Methotrexate Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w; equal numbers of subjects were planned to be assigned to each OKZ treatment group.	Drug: Placebo; sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Experimental: Arm 1: Olokizumab q4w; Olokizumab 64mg subcutaneous q4w + placebo + Methotrexate Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)	Drug: Olokizumab; 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial; Drug: Placebo; sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response	The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (VAS); Patient Assessment of Pain (VAS); HAQ-DI; Physician Global Assessment (VAS); Level of acute phase reactant (CRP)	at Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects Achieving Low Disease Activity	Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) <3.2, and remaining on randomized treatment and in the study at Week 12	at Week 12
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)	Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions.The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI.The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).	Baseline to Week 12
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response	Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (VAS); Patient Assessment of Pain (VAS); HAQ-DI; Physician Global Assessment (VAS); Level of acute phase reactant (CRP)	at Week 12
Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)	Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 12	at Week 12

Collaborators and Investigators

• Sponsor: R-Pharm International, LLC
• Collaborators: Quintiles, Inc.; OCT Clinical Trials; Mene Research
• Investigators: Study Director: Mikhail Samsonov, R-Pharm

Publications and helpful links

General Publications

• Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, Samsonov M, Smolen JS, Fleischmann RM. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Dec;81(12):1661-1668. doi: 10.1136/ard-2022-222630. Epub 2022 Sep 15.

Study record dates

Study Major Dates

• Study Start (Actual): January 25, 2017
• Primary Completion (Actual): September 12, 2019
• Study Completion (Actual): October 1, 2019

Study Registration Dates

• First Submitted: April 29, 2016
• First Submitted That Met QC Criteria: May 2, 2016
• First Posted (Estimated): May 3, 2016

Study Record Updates

• Last Update Posted (Actual): September 21, 2023
• Last Update Submitted That Met QC Criteria: September 19, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Olokizumab; moderate Rheumatoid Arthritis; severe Rheumatoid Arthritis
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Necrosis
• Other Study ID Numbers: CL04041025; 2015-005308-27 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No